NCT05575518

A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis

CompletedPHASE3INTERVENTIONAL

Trial Details

Start: 2023-08-11Est. Completion: 2026-05-25

Enrollment target: 414 participants

Locations

Mycobacterium InfectionsTuberculosis, Multidrug-ResistantLatent TuberculosisTuberculosisExtensively Drug-Resistant Tuberculosis

Background: \- Tuberculosis (TB) is an infectious disease that affects numerous people worldwide. Researchers are inter…

Bethesda, United States

Rifampicin-Resistant Pulmonary TuberculosisMultidrug-Resistant Pulmonary Tuberculosis

This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tol…

Beijing, ChinaEst. completion Sep 29, 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.